Lipodystrophy Severity Does Not Contribute to HAART Nonadherence

Collins, Evan J.; Burgoyne, Robert W.; Wagner, Cheryl A.; Abbey, Susan E.; Halman, Mark H.; Nur, Margaret L.; Walmsley, Sharon L.
May 2006
AIDS & Behavior;May2006, Vol. 10 Issue 3, p273
Academic Journal
Lipodystrophy severity among 77 people living with HIV/AIDS (PHA) with body fat redistribution was not related to antiretroviral adherence including doses missed during the previous month, categorical rating of maximal adherence, and the PMAQ7 adherence behavior scale. Two thirds of the sample reported submaximal adherence, 19% missing more than two doses, but adherence behavior ratings reflected good overall adherence. Overall symptom burden, convenience of regimen schedule and remembering to organize and take antiretroviral doses, but not regimen adaptation or treatment support, were associated with adherence. Remembering was most strongly related to adherence indicators, retaining statistical significance in adjusted multivariate regression analyses.


Related Articles

  • Correction Options for Lipoatrophy in HIV-Infected Patients. Engelhard, Peter // AIDS Patient Care & STDs;Mar2006, Vol. 20 Issue 3, p151 

    Lipoatrophy (LA) is a form of lipodystrophy, characterized by volume depletion caused by fat loss in the limbs, buttocks, and face. Facial volume loss is the most obvious outward sign of LA because it alters the facial contours in the cheeks, temples, and orbits. Lipodystrophy and LA are most...

  • Uridine Metabolism in HIV-1-Infected Patients: Effect of Infection, of Antiretroviral Therapy and of HIV-1/ART-Associated Lipodystrophy Syndrome. Domingo, Pere; Torres-Torronteras, Javier; Pomar, Virginia; Giralt, Marta; Domingo, Joan Carles; Gutierrez, Maria del Mar; Gallego-Escuredo, José M.; Mateo, Maria Gracia; Cano-Soldado, Pedro; Fernandez, Irene; Pastor-Anglada, Marçal; Vidal, Francesc; Villarroya, Francesc; Andreu, Antoni; Marti, Ramon // PLoS ONE;2010, Vol. 5 Issue 11, p1 

    Background: Uridine has been advocated for the treatment of HIV-1/HAART-associated lipodystrophy (HALS), although its metabolism in HIV-1-infected patients is poorly understood. Methods: Plasma uridine concentrations were measured in 35 controls and 221 HIV-1-infected patients and fat uridine in...

  • DisfuncÈ›ia endotelială, lipodistrofia ÅŸi sindromul metabolic la pacienÈ›i infectaÈ›i cu HIV. PAPIȚĂ, ANAMARIA; ALBU, ADRIANA; ITU, CORINA; CÂRSTINA, D. // Romanian Journal of Medical Practice;2010, Vol. 5 Issue 3, p185 

    HIV infection has become in our days a chronic disease due to the efficiency of antiretroviral (ARV) treatment. Soon after the introduction of this treatment its complications related to metabolic disturbances have been observed and studied. Metabolic syndrome was particularly described in...

  • Characteristics Associated to Lipodystrophy Syndrome among HIV-Infected Patients Naive and on Antiretroviral Treatment. Alencastro, Paulo R.; Wolff, Fernando H.; Schuelter-Trevisol, Fabiana; Ikeda, Maria Letícia; Brandão, Ajácio B. M.; Barcellos, Nemora T.; Fuchs, Sandra C. // Journal of AIDS & Clinical Research;2012, Vol. 3 Issue 9, Special section p1 

    Background: HIV-associated lipodystrophy involves changes in complex metabolic networks that are associated with increased cardiovascular risk. It has been associated with the use of combined antiretroviral treatment (cART), particularly Protease Inhibitors (PI) and thymidine analogs. This study...

  • Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive Patients: A 3-Year Randomized Trial. Gallant, Joel E.; Staszewski, Schlomo; Pozniak, Anton L.; DeJesus, Edwin; Suleiman, Jamal M. A. H.; Miller, Michael D.; Coakley, Dion F.; Lu, Biao; Toole, John J.; Cheng, Andrew K. // JAMA: Journal of the American Medical Association;7/14/2004, Vol. 292 Issue 2, p191 

    Context Tenofovir disoproxil fumarate (DF) is a once-daily nucleotide analogue reverse transcriptase inhibitor. Objective To evaluate the efficacy and safety of tenofovir DF compared with stavudine in antiretroviral-naive patients. Design, Setting, and Participants A prospective, randomized,...

  • Antiretrovirals.  // Reactions Weekly;9/13/2008, Issue 1219, p8 

    The article presents a case study of a 37-year-old man who developed human immunodeficiency virus (HIV)-associated lipodystrophy syndrome while receiving various antiretrovirals for HIV. The patient also developed anaemia during zidovudine therapy, peripheral neuropathy while receiving...

  • Lipodystrophy Syndrome by HAART in HIV-Infected Patients: Manifestation, Mechanisms and Management. Hirsch, H. H.; Battegay, M. // Infection;Oct2002, Vol. 30 Issue 5, p293 

    Progressive changes in the distributions of body fat and severe alterations of lipid, glucose and lactate levels challenge the mid and long-term success of highly active antiretroviral therapy of HIV-infection. Both clinical diagnosis of the lipodystrophy syndrome and scientific elucidation of...

  • THE ROLE OF EXERCISE WITH HIV. Irwin, Melissa // HealthEX Specialist;2005, Issue 5, p9 

    Discusses the impact of exercise interventions on long-term effects of Human Immunodeficiency Virus (HIV) and Highly Active Antriretroviral Therapy (HAART) in Great Britain. Background on HIV and HAART; Overview of the long-term effects of HIV and HAART, including body fat redistribution or...

  • A Randomized, Placebo-Controlled Trial of Rosiglitazone for HIV-Related Lipoatrophy. Cavalcanti, Rodrigo B.; Raboud, Janet; Shen, Sandy; Kain, Kevin C.; Cheung, Angela; Walmsley, Sharon // Journal of Infectious Diseases;6/15/2007, Vol. 195 Issue 12, p1754 

    Background. Thiazolidinediones such as rosiglitazone may have benefit in ameliorating human immunodeficiency virus (HIV) lipoatrophy. Methods. HIV-positive patients receiving stable, protease inhibitor-containing highly active antiretroviral therapy with HIV lipodystrophy were prospectively...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics